Join our daily newsletter At The Bell to receive exclusive market insights
- Health and beauty technologies business, Anagenics (AN1), has appointed its financial controller Matthew Dudek as acting CEO
- Following the resignation of CEO and Managing Director Maria Halasz, Mr Dudek’s new position was effective from February 28
- Under a 12 month contract, Mr Dudek is on a base salary of $250,000 and during this time he and the company will determine whether a permanent CEO role is suitable
- The new CEO says he is honoured to take over the position and looks forward to delivering on AN1’s key objectives and leading the next stage of growth
- Shares have been trading grey at 4.9 cents at 2:20 pm AEDT
Health and beauty technologies business, Anagenics (AN1), has appointed its financial controller Matthew Dudek as acting CEO.
Following the resignation of CEO and Managing Director Maria Halasz, Mr Dudek’s new position was effective from February 28.
The position is for a term of 12 months and will see Mr Dudek receive a base salary of $250,000 excluding superannuation.
During the 12-month period, he and the company, can determine whether a permanent CEO role is suitable and if so a new contract will be put in place.
The internal appointment follows a board reshuffle as AN1 transitions to a “digitally-driven” company.
With a foundation of differentiated brands, a global distribution footprint, improved digital platforms and a strategy that includes organic growth and acquisitions, Ms Halasz decided it was time to step down and assisted with the selection of the new CEO.
According to the company, since 2020, Mr Dudek has played a key role in day-to-day management while in the position of Financial Controller. He reportedly has a deep knowledge of the business and a strong track record in implementing profit improvement initiatives and strategies.
In his new role, Mr Dudek will be supported by a senior executive team which includes Chief Operating Officer Dr Dominic Burg and General Manager of Sales Carolyn Heath.
Mr Dudek said he is honoured to take over the role.
“Anagenics is an exciting company with strong intellectual property, highly differentiated products and global potential,” he said.
“I am looking forward to delivering on our objectives and leading our next stage of growth”.
Shares were trading grey at 4.9 cents at 2:20 pm AEDT.
